Stepan Reports Fourth Quarter 2024 Results
Fourth Quarter 2024 Highlights
- Reported net income was
$3.4 million versus a$1.2 million net loss in the prior year. Adjusted net income(1) was$2.8 million , down 63% versus prior year, largely due to higher pre-commissioning expenses at our new alkoxylation investment inPasadena, Texas ($4.4 million increase), a one-time tax proceeding reserve of$2.9 million recorded in our Latin American operations and higher expenses associated with the previously announced CEO transition in the fourth quarter of 2024. - EBITDA(2) was
$35.8 million and Adjusted EBITDA(2) was$35.0 million , up 39% and down 7% respectively, year-over-year. - Global sales volume was down 1% year-over-year. Double digit growth in several Surfactant end markets was fully offset by demand weakness in Polymers.
- Cash from Operations was
$68.3 million during the quarter. Free cash flow(3) for the quarter was$32.1 million . - The Company delivered
$13.0 million in pre-tax cost out savings in the fourth quarter of 2024.
YTD 2024 Highlights
- Reported net income was
$50.4 million , up 25% versus prior year. Adjusted net income(1) was$50.5 million , flat versus prior year. - EBITDA(2) was
$186.9 million and Adjusted EBITDA(2) was$187.0 million , up 13% and 4% respectively, year-over-year. - Global sales volume was up 1% year-over-year.
- Free cash flow(3) for the year was
$39.3 million versus a negative$85.5 million in the prior year. - The Company delivered
$48.0 million in cost out savings for 2024 despite significant one-time extra costs, including higher operating costs at our Millsdale site, primarily related to a flood event during the first half of 2024, and higher costs related to a criminal fraud event at a subsidiary inAsia .
"While we are disappointed with our overall financial performance in 2024, we advanced our strategic investments and took necessary steps to return the Company to profitable growth. I am proud of the resilience, hard work and dedication of the entire organization. Full year Adjusted EBITDA grew 4% versus prior year despite several one-time events that negatively impacted earnings and the pre-operating expenses in our new
Financial Summary
|
Three Months Ended |
Twelve Months Ended |
|||||||||||||||||||||||
|
($ in thousands, except per share data) |
2024 |
2023 |
% |
2024 |
2023 |
% |
||||||||||||||||||
|
|
$ |
525,609 |
$ |
532,131 |
(1) |
% |
$ |
2,180,274 |
$ |
2,325,768 |
(6) |
% |
||||||||||||
|
Operating Income |
$ |
7,695 |
$ |
230 |
NM |
$ |
70,480 |
$ |
58,613 |
20 |
% |
|||||||||||||
|
Net Income |
$ |
3,350 |
$ |
(1,193) |
NM |
$ |
50,370 |
$ |
40,204 |
25 |
% |
|||||||||||||
|
Earnings per Diluted Share |
$ |
0.15 |
$ |
(0.05) |
NM |
$ |
2.20 |
$ |
1.75 |
26 |
% |
|||||||||||||
|
Adjusted Net Income * |
$ |
2,757 |
$ |
7,485 |
(63) |
% |
$ |
50,470 |
$ |
50,692 |
(0) |
% |
||||||||||||
|
Adjusted Earnings per |
$ |
0.12 |
$ |
0.33 |
(64) |
% |
$ |
2.20 |
$ |
2.21 |
(0) |
% |
||||||||||||
|
* See Table II for reconciliations of non-GAAP adjusted net income and adjusted earnings per diluted share. |
|
Percentage Change in
Net sales in the fourth quarter of 2024 decreased 1% year-over-year. This slight decrease reflects higher selling prices that were more than offset by a 1% decline in sales volume and the negative impact of foreign currency translation.
|
Three Months Ended |
Twelve Months Ended |
|||||||
|
Volume |
(1) |
% |
1 |
% |
||||
|
Selling Price & Mix |
2 |
% |
(7) |
% |
||||
|
Foreign Translation |
(2) |
% |
(—) |
% |
||||
|
Total |
(1) |
% |
(6) |
% |
||||
Segment Results
|
Three Months Ended |
Twelve Months Ended |
|||||||||||||||||||||||
|
($ in thousands) |
2024 |
2023 |
% |
2024 |
2023 |
% |
||||||||||||||||||
|
|
||||||||||||||||||||||||
|
Surfactants |
$ |
378,776 |
$ |
369,468 |
3 |
% |
$ |
1,532,115 |
$ |
1,602,819 |
(4) |
% |
||||||||||||
|
Polymers |
$ |
129,844 |
$ |
147,271 |
(12) |
% |
$ |
584,905 |
$ |
642,471 |
(9) |
% |
||||||||||||
|
Specialty Products |
$ |
16,989 |
$ |
15,392 |
10 |
% |
$ |
63,254 |
$ |
80,478 |
(21) |
% |
||||||||||||
|
Total |
$ |
525,609 |
$ |
532,131 |
(1) |
% |
$ |
2,180,274 |
$ |
2,325,768 |
(6) |
% |
||||||||||||
|
Three Months Ended |
Twelve Months Ended |
|||||||||||||||||||||||
|
($ in thousands, all amounts pre-tax) |
2024 |
2023 |
% |
2024 |
2023 |
% |
||||||||||||||||||
|
Operating Income |
||||||||||||||||||||||||
|
Surfactants |
$ |
16,173 |
$ |
14,830 |
9 |
% |
$ |
85,618 |
$ |
72,399 |
18 |
% |
||||||||||||
|
Polymers |
$ |
3,396 |
$ |
12,632 |
(73) |
% |
$ |
40,623 |
$ |
60,770 |
(33) |
% |
||||||||||||
|
Specialty Products |
$ |
5,594 |
$ |
2,773 |
102 |
% |
$ |
20,908 |
$ |
11,476 |
82 |
% |
||||||||||||
|
Total Segment |
$ |
25,163 |
$ |
30,235 |
(17) |
% |
$ |
147,149 |
$ |
144,645 |
2 |
% |
||||||||||||
|
Corporate Expenses |
$ |
(17,468) |
$ |
(30,005) |
(42) |
% |
$ |
(76,669) |
$ |
(86,032) |
(11) |
% |
||||||||||||
|
Consolidated |
$ |
7,695 |
$ |
230 |
3,246 |
% |
$ |
70,480 |
$ |
58,613 |
20 |
% |
||||||||||||
|
Three Months Ended |
Year Ended |
|||||||||||||||||||||||
|
($ in millions) |
2024 |
2023 |
% |
2024 |
2023 |
% |
||||||||||||||||||
|
EBITDA |
$ |
35.8 |
$ |
25.8 |
39 |
% |
$ |
186.9 |
$ |
165.8 |
13 |
% |
||||||||||||
|
Adjusted EBITDA |
||||||||||||||||||||||||
|
Surfactants |
$ |
34.7 |
$ |
31.6 |
10 |
% |
$ |
157.6 |
$ |
136.7 |
15 |
% |
||||||||||||
|
Polymers |
$ |
11.4 |
$ |
20.5 |
(44) |
% |
$ |
73.0 |
$ |
93.2 |
(22) |
% |
||||||||||||
|
Specialty Products |
$ |
7.1 |
$ |
4.3 |
65 |
% |
$ |
26.9 |
$ |
17.3 |
55 |
% |
||||||||||||
|
Unallocated Corporate |
$ |
(18.2) |
$ |
(18.9) |
(4) |
% |
$ |
(70.5) |
$ |
(67.2) |
5 |
% |
||||||||||||
|
Consolidated Adjusted EBITDA |
$ |
35.0 |
$ |
37.5 |
(7) |
% |
$ |
187.0 |
$ |
180.0 |
4 |
% |
||||||||||||
Consolidated operating income in the quarter increased
- Surfactant net sales were
$378.8 million for the quarter, a 3% increase versus the prior year. Selling prices were up 5% primarily due to improved product and customer mix. Sales volume was up 1% year-over-year primarily due to double digit growth within the Agricultural and Oilfield end markets along with our distribution partners. This growth was partially offset by lower demand within the Consumer Products end markets. Foreign currency translation negatively impacted net sales by 3%. Surfactant operating income for the quarter increased$1.3 million , or 9%, versus the prior year. Surfactant adjusted EBITDA(2) increased$3.1 million , or 10%, versus the prior year. This increase was primarily driven by the 1% growth in sales volume and slight margin improvement, partially offset by pre-operating expenses at the Company's new alkoxylation facility being built inPasadena, Texas and the tax proceeding reserve recognized in Latin American operations. - Polymer net sales were
$129.8 million for the quarter, a 12% decrease versus the prior year. Selling prices decreased 4%, primarily due to the pass-through of lower raw material costs and competitive pressures. Sales volume declined 9% in the quarter primarily due to an 11% decrease in global Rigid Polyols demand. Specialty Polyols volume was up year-over-year. Foreign currency translation positively impacted net sales by 1%. Polymer operating income decreased$9.2 million , or 73%, versus the prior year. Polymer adjusted EBITDA(2) decreased$9.1 million , or 44%, versus the prior year primarily due to the 9% decline in sales volume. - Specialty Product net sales were
$17.0 million for the quarter, a 10% increase versus the prior year, primarily due to higher sales volume and higher selling prices. Sales volume was up 32% versus the prior year. Specialty Product operating income increased$2.8 million , or 102%, versus the prior year. Specialty Product adjusted EBITDA(2) increased$2.8 million , or 65%. The increase in adjusted EBITDA(2) was primarily due to margin recovery and higher sales volume within the medium chain triglycerides product line.
Income Taxes
The Company's full year effective tax rate was 16.7% in 2024 versus 16.9% in 2023. This small decrease was comprised of various offsetting items, most notably a favorable non-recurring deferred tax adjustment in 2024 that offset an unfavorable foreign rate differential in 2024.
Outlook
"As we look forward to 2025, I am excited and energized to continue our focus on accelerating our business strategies through improved execution to drive consistent volume growth, margin improvement and free cash flow generation. We believe Adjusted EBITDA will improve in all of our reporting segments. The Stepan Team is executing on opportunities to grow volume, deliver improved product and customer mix and further progress our cost out and cost avoidance initiatives. We are optimistic that Polymer demand will increase as we execute our innovation and growth plans. We believe our Surfactant business will experience continued growth in our key strategic end markets," said
|
Notes |
|
|
(1) |
Adjusted net income and adjusted earnings per share are non-GAAP measures which exclude deferred compensation income/expense, cash-settled stock appreciation rights (SARs) income/expense, certain environmental remediation-related costs as well as other significant and infrequent/non-recurring items. See Table II for reconciliations of non-GAAP adjusted net income and adjusted earnings per diluted share. |
|
(2) |
EBITDA and adjusted EBITDA are non-GAAP measures. See Table VI for calculations and GAAP reconciliations of EBITDA and adjusted EBITDA. |
|
(3) |
Free cash flow is a non-GAAP measure and reflects cash generated from operations minus capital expenditures. Cash generated from operations was |
Conference Call
Supporting Slides
Slides supporting this press release will be made available at www.stepan.com through the Investors/Presentations page at approximately the same time as this press release is issued.
Corporate Profile
Headquartered in
The Company's common stock is traded on the
More information about Stepan's sustainability program can be found on the Sustainability page at www.stepan.com
Certain information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements about
There are a number of risks, uncertainties and other important factors, many of which are beyond
These forward-looking statements are made only as of the date hereof, and
Tables follow
|
Table I |
||||||||||||||||
|
|
||||||||||||||||
|
For the Three and Twelve Months Ended |
||||||||||||||||
|
(Unaudited – in 000's, except per share data) |
||||||||||||||||
|
Three Months Ended |
Twelve Months Ended |
|||||||||||||||
|
2024 |
2023 |
2024 |
2023 |
|||||||||||||
|
|
$ |
525,609 |
$ |
532,131 |
$ |
2,180,274 |
$ |
2,325,768 |
||||||||
|
Cost of Sales |
468,913 |
465,726 |
1,908,060 |
2,048,170 |
||||||||||||
|
Gross Profit |
56,696 |
66,405 |
272,214 |
277,598 |
||||||||||||
|
Operating Expenses: |
||||||||||||||||
|
Selling |
11,018 |
12,380 |
45,628 |
48,367 |
||||||||||||
|
Administrative |
24,764 |
25,070 |
98,277 |
93,202 |
||||||||||||
|
Research, Development and Technical Services |
13,793 |
15,319 |
55,674 |
59,039 |
||||||||||||
|
Deferred Compensation Expense (Income) |
(574) |
5,227 |
2,155 |
4,371 |
||||||||||||
|
49,001 |
57,996 |
201,734 |
204,979 |
|||||||||||||
|
|
- |
2,038 |
- |
2,038 |
||||||||||||
|
Business Restructuring and Asset Impairment |
- |
6,141 |
- |
11,968 |
||||||||||||
|
Operating Income |
7,695 |
230 |
70,480 |
58,613 |
||||||||||||
|
Other Income (Expense): |
||||||||||||||||
|
Interest, Net |
(4,829) |
(2,429) |
(14,182) |
(12,103) |
||||||||||||
|
Other, Net |
(410) |
(1,467) |
4,141 |
1,881 |
||||||||||||
|
(5,239) |
(3,896) |
(10,041) |
(10,222) |
|||||||||||||
|
Income Before Provision for Income Taxes |
2,456 |
(3,666) |
60,439 |
48,391 |
||||||||||||
|
Provision for Income Taxes |
(894) |
(2,473) |
10,069 |
8,187 |
||||||||||||
|
Net Income |
3,350 |
(1,193) |
50,370 |
40,204 |
||||||||||||
|
Net Income Per Common Share |
||||||||||||||||
|
Basic |
$ |
0.15 |
$ |
(0.05) |
$ |
2.21 |
$ |
1.77 |
||||||||
|
Diluted |
$ |
0.15 |
$ |
(0.05) |
$ |
2.20 |
$ |
1.75 |
||||||||
|
Shares Used to Compute Net Income Per |
||||||||||||||||
|
Basic |
22,841 |
22,794 |
22,832 |
22,777 |
||||||||||||
|
Diluted |
22,912 |
22,912 |
22,931 |
22,946 |
||||||||||||
|
Table II |
||||||||||||||||||||||||||||||||
|
Reconciliation of Non-GAAP Net Income and Earnings per Diluted Share* |
||||||||||||||||||||||||||||||||
|
Three Months Ended |
Twelve Months Ended |
|||||||||||||||||||||||||||||||
|
($ in thousands, except per share amounts) |
2024 |
EPS |
2023 |
EPS |
2024 |
EPS |
2023 |
EPS |
||||||||||||||||||||||||
|
Net Income Reported |
$ |
3,350 |
$ |
0.15 |
$ |
(1,193) |
$ |
(0.05) |
$ |
50,370 |
$ |
2.20 |
$ |
40,204 |
$ |
1.75 |
||||||||||||||||
|
Deferred Compensation |
$ |
(762) |
$ |
(0.03) |
$ |
2,243 |
$ |
0.10 |
$ |
(1,805) |
$ |
(0.08) |
$ |
(551) |
$ |
(0.02) |
||||||||||||||||
|
Business Restructuring and Asset |
$ |
- |
$ |
- |
$ |
4,564 |
$ |
0.20 |
$ |
- |
$ |
- |
$ |
8,929 |
$ |
0.39 |
||||||||||||||||
|
|
$ |
- |
$ |
- |
$ |
1,422 |
$ |
0.06 |
$ |
- |
$ |
- |
$ |
1,422 |
$ |
0.06 |
||||||||||||||||
|
Cash-Settled SARs (Income) Expense |
$ |
- |
$ |
- |
$ |
71 |
$ |
- |
$ |
- |
$ |
- |
$ |
(74) |
$ |
- |
||||||||||||||||
|
Environmental Remediation |
$ |
169 |
$ |
- |
$ |
378 |
$ |
0.02 |
$ |
1,905 |
$ |
0.08 |
$ |
762 |
$ |
0.03 |
||||||||||||||||
|
Adjusted Net Income |
$ |
2,757 |
$ |
0.12 |
$ |
7,485 |
$ |
0.33 |
$ |
50,470 |
$ |
2.20 |
$ |
50,692 |
$ |
2.21 |
||||||||||||||||
|
* All amounts in this table are presented after-tax |
The Company believes that certain non-GAAP measures, in conjunction with comparable GAAP measures, are useful for evaluating the Company's operating performance and financial condition. The Company uses this non-GAAP information as an indicator of business performance and evaluates management's effectiveness with specific reference to these indicators. Management believes that these non-GAAP financial measures provide useful supplemental information because they exclude non-operational items that affect comparability between years. These measures should be considered in addition to, not as substitutes for or superior to, measures of financial performance prepared in accordance with GAAP and may differ from similarly titled measures presented by other companies. The Company's Annual Report on Form 10-K for the year ended
Summary of Fourth Quarter 2024 Adjusted Net Income Items
Adjusted net income excludes non-operational deferred compensation income/expense, cash-settled SARs income/expense, certain environmental remediation costs and other significant and infrequent or non-recurring items.
- Deferred Compensation: The fourth quarter of 2024 reported net income includes
$0.8 million of after-tax income versus$2.2 million of after-tax expense in the prior year. - Environmental Remediation: The fourth quarter of 2024 reported net income includes
$0.2 million of after-tax expense versus$0.4 million of after-tax expense in the prior year.
|
Table III |
||||||||||||||||||||||||||||||||
|
Reconciliation of Pre-Tax to After-Tax Adjustments |
||||||||||||||||||||||||||||||||
|
Management uses the non-GAAP adjusted net income metric to evaluate the Company's operating performance. Management excludes the items listed in the table below because they are non-operational items. The cumulative tax effect was calculated using the statutory tax rates for the jurisdictions in which the transactions occurred. |
||||||||||||||||||||||||||||||||
|
Three Months Ended |
Twelve Months Ended |
|||||||||||||||||||||||||||||||
|
($ in thousands, except per share amounts) |
2024 |
EPS |
2023 |
EPS |
2024 |
EPS |
2023 |
EPS |
||||||||||||||||||||||||
|
Pre-Tax Adjustments |
||||||||||||||||||||||||||||||||
|
Deferred Compensation (Income) Expense |
$ |
(1,016) |
$ |
2,991 |
$ |
(2,406) |
$ |
(735) |
||||||||||||||||||||||||
|
Business Restructuring and Asset Impairment Expense |
$ |
- |
$ |
6,141 |
$ |
- |
$ |
11,968 |
||||||||||||||||||||||||
|
|
$ |
- |
$ |
2,038 |
$ |
- |
$ |
2,038 |
||||||||||||||||||||||||
|
Cash-Settled SARs (Income) Expense |
$ |
- |
$ |
95 |
$ |
- |
$ |
(98) |
||||||||||||||||||||||||
|
Environmental Remediation Expense |
$ |
225 |
$ |
504 |
$ |
2,540 |
$ |
1,017 |
||||||||||||||||||||||||
|
Total Pre-Tax Adjustments |
$ |
(791) |
$ |
11,769 |
$ |
134 |
$ |
14,190 |
||||||||||||||||||||||||
|
Cumulative Tax Effect on Adjustments |
$ |
198 |
$ |
(3,091) |
$ |
(34) |
$ |
(3,702) |
||||||||||||||||||||||||
|
After-Tax Adjustments |
$ |
(593) |
$ |
(0.03) |
$ |
8,678 |
$ |
0.38 |
$ |
100 |
$ |
0.00 |
$ |
10,488 |
$ |
0.46 |
||||||||||||||||
|
Table IV |
||||||||||||||||||||||||||||||||
|
Deferred Compensation Plans |
||||||||||||||||||||||||||||||||
|
The full effect of the deferred compensation plans on quarterly pre-tax income was |
||||||||||||||||||||||||||||||||
|
2024 |
2023 |
|||||||||||||||||||||||||||||||
|
12/31 |
9/30 |
6/30 |
3/31 |
12/31 |
9/30 |
6/30 |
3/31 |
|||||||||||||||||||||||||
|
|
$ |
64.70 |
$ |
77.25 |
$ |
83.96 |
$ |
90.04 |
$ |
94.55 |
$ |
74.97 |
$ |
95.56 |
$ |
103.03 |
||||||||||||||||
|
Three Months Ended |
Twelve Months Ended |
|||||||||||||||
|
($ in thousands) |
2024 |
2023 |
2024 |
2023 |
||||||||||||
|
Deferred Compensation |
||||||||||||||||
|
Operating Income (Expense) |
$ |
574 |
$ |
(5,227) |
$ |
(2,155) |
$ |
(4,371) |
||||||||
|
Other, net – Mutual Fund Gain (Loss) |
442 |
2,236 |
4,561 |
5,106 |
||||||||||||
|
Total Pre-Tax |
$ |
1,016 |
$ |
(2,991) |
$ |
2,406 |
$ |
735 |
||||||||
|
Total After-Tax |
$ |
762 |
$ |
(2,243) |
$ |
1,805 |
$ |
551 |
||||||||
|
Effects of Foreign Currency Translation |
||||||||||||||||||||||||||||||||
|
The Company's foreign subsidiaries transact business and report financial results in their respective local currencies. These results are translated into |
||||||||||||||||||||||||||||||||
|
($ in millions) |
Three Months Ended |
Change |
Change |
Twelve Months Ended |
Change |
Change |
||||||||||||||||||||||||||
|
2024 |
2023 |
2024 |
2023 |
|||||||||||||||||||||||||||||
|
|
$ |
525.6 |
$ |
532.1 |
$ |
(6.5) |
$ |
(9.6) |
$ |
2,180.3 |
$ |
2,325.8 |
$ |
(145.5) |
$ |
(2.5) |
||||||||||||||||
|
Gross Profit |
56.7 |
66.4 |
$ |
(9.7) |
(1.1) |
272.2 |
277.6 |
$ |
(5.4) |
(1.0) |
||||||||||||||||||||||
|
Operating Income |
7.7 |
0.2 |
$ |
7.5 |
(1.0) |
70.5 |
58.6 |
$ |
11.9 |
(0.8) |
||||||||||||||||||||||
|
Pretax Income |
2.5 |
(3.7) |
$ |
6.2 |
0.2 |
60.4 |
48.4 |
$ |
12.0 |
0.1 |
||||||||||||||||||||||
|
Corporate Expenses |
||||||||||||||||||||||||
|
Three Months Ended |
Twelve Months Ended |
|||||||||||||||||||||||
|
($ in thousands) |
2024 |
2023 |
% |
2024 |
2023 |
% |
||||||||||||||||||
|
Total Corporate Expenses |
$ |
17,468 |
$ |
30,005 |
(42) |
% |
$ |
76,669 |
$ |
86,032 |
(11) |
% |
||||||||||||
|
Less: |
||||||||||||||||||||||||
|
Deferred Compensation (Income) Expense |
$ |
(574) |
$ |
5,227 |
NM |
$ |
2,155 |
$ |
4,371 |
(51) |
% |
|||||||||||||
|
Business Restructuring and Asset |
$ |
- |
$ |
6,141 |
(100) |
% |
$ |
- |
$ |
11,968 |
(100) |
% |
||||||||||||
|
|
$ |
- |
$ |
2,038 |
(100) |
% |
$ |
- |
$ |
2,038 |
(100) |
% |
||||||||||||
|
Environmental Remediation |
$ |
225 |
$ |
504 |
(55) |
% |
$ |
2,540 |
$ |
1,017 |
150 |
% |
||||||||||||
|
Adjusted Corporate Expenses |
$ |
17,817 |
$ |
16,095 |
11 |
% |
$ |
71,974 |
$ |
66,638 |
8 |
% |
||||||||||||
Adjusted Corporate expenses increased
|
Table V |
||||||||
|
|
||||||||
|
Consolidated Balance Sheets |
||||||||
|
|
||||||||
|
|
|
|||||||
|
ASSETS |
||||||||
|
Current Assets |
$ |
810,429 |
$ |
851,883 |
||||
|
Property, Plant & Equipment, Net |
1,198,454 |
1,206,665 |
||||||
|
Other Assets |
295,765 |
304,806 |
||||||
|
Total Assets |
$ |
2,304,648 |
$ |
2,363,354 |
||||
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
||||||||
|
Current Liabilities |
$ |
669,034 |
$ |
607,870 |
||||
|
Deferred Income Taxes |
9,612 |
10,373 |
||||||
|
Long-term Debt |
332,632 |
401,248 |
||||||
|
Other Non-current Liabilities |
123,436 |
127,373 |
||||||
|
Total Stepan Company Stockholders' Equity |
1,169,934 |
1,216,490 |
||||||
|
Total Liabilities and Stockholders' Equity |
$ |
2,304,648 |
$ |
2,363,354 |
||||
|
Selected Balance Sheet Information |
|||||||||||||||||||
|
The Company's total debt decreased by |
|||||||||||||||||||
|
($ in millions) |
|
|
|
|
|
||||||||||||||
|
Net Debt |
|||||||||||||||||||
|
Total Debt |
$ |
625.4 |
$ |
688.5 |
$ |
657.1 |
$ |
646.0 |
$ |
654.1 |
|||||||||
|
Cash |
99.7 |
147.3 |
124.7 |
125.8 |
129.8 |
||||||||||||||
|
Net Debt |
$ |
525.7 |
$ |
541.2 |
$ |
532.4 |
$ |
520.2 |
$ |
524.3 |
|||||||||
|
Equity |
1,169.9 |
1,219.4 |
1,192.4 |
1,214.5 |
1,216.5 |
||||||||||||||
|
Net Debt + Equity |
$ |
1,695.6 |
$ |
1,760.6 |
$ |
1,724.8 |
$ |
1,734.7 |
$ |
1,740.8 |
|||||||||
|
Net Debt / (Net Debt + Equity) |
31 |
% |
31 |
% |
31 |
% |
30 |
% |
30 |
% |
|||||||||
|
The major working capital components were: |
|
($ in millions) |
|
|
|
|
|
||||||||||||||
|
Net Receivables |
$ |
388.0 |
$ |
434.1 |
$ |
437.3 |
$ |
446.6 |
$ |
422.1 |
|||||||||
|
Inventories |
288.7 |
296.7 |
266.0 |
257.1 |
265.6 |
||||||||||||||
|
Accounts Payable |
(258.8) |
(257.1) |
(251.2) |
(256.9) |
(233.0) |
||||||||||||||
|
$ |
417.9 |
$ |
473.7 |
$ |
452.1 |
$ |
446.8 |
$ |
454.7 |
||||||||||
|
Table VI |
||||||||||||||||||||
|
Reconciliations of Non-GAAP EBITDA and Adjusted EBITDA |
||||||||||||||||||||
|
Management uses the non-GAAP EBITDA and adjusted EBITDA metrics to evaluate the Company's operating performance. Management excludes the items listed in the table below because they are non-operational items. Refer to the Income Statement on Table I for a bridge between Operating Income and Net Income. |
||||||||||||||||||||
|
Three Months Ended |
||||||||||||||||||||
|
($ in millions) |
Surfactants |
Polymers |
Specialty |
Unallocated |
Consolidated |
|||||||||||||||
|
Operating Income |
$ |
16.2 |
$ |
3.4 |
$ |
5.6 |
$ |
(17.5) |
$ |
7.7 |
||||||||||
|
Depreciation and Amortization |
$ |
18.5 |
$ |
8.0 |
$ |
1.5 |
$ |
0.5 |
$ |
28.5 |
||||||||||
|
Other, Net Income |
$ |
- |
$ |
- |
$ |
- |
$ |
(0.4) |
$ |
(0.4) |
||||||||||
|
EBITDA |
$ |
35.8 |
||||||||||||||||||
|
Deferred Compensation |
$ |
- |
$ |
- |
$ |
- |
$ |
(1.0) |
$ |
(1.0) |
||||||||||
|
Environmental Remediation |
$ |
- |
$ |
- |
$ |
- |
$ |
0.2 |
$ |
0.2 |
||||||||||
|
Adjusted EBITDA |
$ |
34.7 |
$ |
11.4 |
$ |
7.1 |
$ |
(18.2) |
$ |
35.0 |
||||||||||
|
Three Months Ended |
||||||||||||||||||||
|
($ in millions) |
Surfactants |
Polymers |
Specialty |
Unallocated |
Consolidated |
|||||||||||||||
|
Operating Income |
$ |
14.8 |
$ |
12.6 |
$ |
2.8 |
$ |
(30.0) |
$ |
0.2 |
||||||||||
|
Depreciation and Amortization |
$ |
16.7 |
$ |
7.9 |
$ |
1.5 |
$ |
1.0 |
$ |
27.1 |
||||||||||
|
Other, Net Income |
$ |
- |
$ |
- |
$ |
- |
$ |
(1.5) |
$ |
(1.5) |
||||||||||
|
EBITDA |
$ |
25.8 |
||||||||||||||||||
|
Deferred Compensation |
$ |
- |
$ |
- |
$ |
- |
$ |
3.0 |
$ |
3.0 |
||||||||||
|
Cash Settled SARs |
$ |
0.1 |
$ |
- |
$ |
- |
$ |
- |
$ |
0.1 |
||||||||||
|
|
$ |
- |
$ |
- |
$ |
- |
$ |
2.0 |
$ |
2.0 |
||||||||||
|
Business Restructuring/ |
$ |
- |
$ |
- |
$ |
- |
$ |
6.1 |
$ |
6.1 |
||||||||||
|
Environmental Remediation |
$ |
- |
$ |
- |
$ |
- |
$ |
0.5 |
$ |
0.5 |
||||||||||
|
Adjusted EBITDA |
$ |
31.6 |
$ |
20.5 |
$ |
4.3 |
$ |
(18.9) |
$ |
37.5 |
||||||||||
|
Twelve Months Ended |
||||||||||||||||||||
|
($ in millions) |
Surfactants |
Polymers |
Specialty |
Unallocated |
Consolidated |
|||||||||||||||
|
Operating Income |
$ |
85.6 |
$ |
40.6 |
$ |
20.9 |
$ |
(76.6) |
$ |
70.5 |
||||||||||
|
Depreciation and Amortization |
$ |
72.0 |
$ |
32.4 |
$ |
6.0 |
$ |
1.9 |
$ |
112.3 |
||||||||||
|
Other, Net Income |
$ |
- |
$ |
- |
$ |
- |
$ |
4.1 |
$ |
4.1 |
||||||||||
|
EBITDA |
$ |
186.9 |
||||||||||||||||||
|
Deferred Compensation |
$ |
- |
$ |
- |
$ |
- |
$ |
(2.4) |
$ |
(2.4) |
||||||||||
|
Environmental Remediation |
$ |
- |
$ |
- |
$ |
- |
$ |
2.5 |
$ |
2.5 |
||||||||||
|
Adjusted EBITDA |
$ |
157.6 |
$ |
73.0 |
$ |
26.9 |
$ |
(70.5) |
$ |
187.0 |
||||||||||
|
Twelve Months Ended |
||||||||||||||||||||
|
($ in millions) |
Surfactants |
Polymers |
Specialty |
Unallocated |
Consolidated |
|||||||||||||||
|
Operating Income |
$ |
72.4 |
$ |
60.8 |
$ |
11.5 |
$ |
(86.0) |
$ |
58.6 |
||||||||||
|
Depreciation and Amortization |
$ |
64.4 |
$ |
32.4 |
$ |
5.8 |
$ |
2.7 |
$ |
105.3 |
||||||||||
|
Other, Net Income (Expense) |
$ |
- |
$ |
- |
$ |
- |
$ |
1.9 |
$ |
1.9 |
||||||||||
|
EBITDA |
$ |
165.8 |
||||||||||||||||||
|
Deferred Compensation |
$ |
- |
$ |
- |
$ |
- |
$ |
(0.7) |
$ |
(0.7) |
||||||||||
|
Cash Settled SARs |
$ |
(0.1) |
$ |
- |
$ |
- |
$ |
- |
$ |
(0.1) |
||||||||||
|
|
$ |
- |
$ |
- |
$ |
- |
$ |
2.0 |
$ |
2.0 |
||||||||||
|
Business Restructuring/ |
$ |
- |
$ |
- |
$ |
- |
$ |
12.0 |
$ |
12.0 |
||||||||||
|
Environmental Remediation |
$ |
- |
$ |
- |
$ |
- |
$ |
1.0 |
$ |
1.0 |
||||||||||
|
Adjusted EBITDA |
$ |
136.7 |
$ |
93.2 |
$ |
17.3 |
$ |
(67.2) |
$ |
180.0 |
||||||||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/stepan-reports-fourth-quarter-2024-results-302379827.html
SOURCE
Samuel S. Hinrichsen 847-446-7500